← back to search

Julia T. Geyer

Cornell University · US
Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Lymphoma Diagnosis and Treatment, and Chronic Lymphocytic Leukemia Research.
h-index
28
citations
6,504
works
124
NIH funding
primary concept
Medicine
email

Recent publications

Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748
Leukemia 2023cited by 59position: middledoi
Spatial mapping of human hematopoiesis at single-cell resolution reveals aging-associated topographic remodeling
Blood 2023cited by 33position: middledoi
Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group
JCO Precision Oncology 2023cited by 13position: middledoi
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Leukemia 2022cited by 3,622position: middledoi
Genetic and phenotypic attributes of splenic marginal zone lymphoma
Blood 2021cited by 95position: middledoi
Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group
Modern Pathology 2021cited by 17position: middledoi
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Blood Advances 2019cited by 66position: middledoi
Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group
Modern Pathology 2019cited by 41position: middledoi
Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T‐ALL like mutations
American Journal of Hematology 2018cited by 61position: middledoi
Myeloproliferative neoplasms with concurrent BCR–ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group
Modern Pathology 2018cited by 49position: middledoi
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome
Haematologica 2017cited by 77position: middledoi
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia
Modern Pathology 2017cited by 73position: firstdoi
Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia
Modern Pathology 2017cited by 24position: middledoi
Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations
Blood 2016cited by 157position: middledoi
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified
Modern Pathology 2016cited by 127position: middledoi
Idelalisib-associated Colitis
The American Journal of Surgical Pathology 2015cited by 160position: middledoi
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
Blood 2014cited by 204position: middledoi
Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up
Haematologica 2014cited by 105position: middledoi
Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease
Modern Pathology 2012cited by 85position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Attilio Orazi · Providence Hospital10 papers (2012–2021)Adam Bagg · Abramson Cancer Center8 papers (2014–2021)Robert P. Hasserjian · Harvard University8 papers (2014–2021)Heesun J. Rogers · Cleveland Clinic7 papers (2014–2021)Daniel A. Arber · University of Illinois Chicago7 papers (2014–2021)Sa A. Wang · Western Oncolytics (United States)7 papers (2014–2021)Eric D. Hsi · Mayo Clinic7 papers (2014–2021)Carlos E. Bueso‐Ramos · The University of Texas MD Anderson Cancer Center5 papers (2014–2021)Srđan Verstovšek · Karus Therapeutics (United Kingdom)4 papers (2014–2021)Wayne Tam · Donald & Barbara Zucker School of Medicine at Hofstra/Northwell3 papers (2016–2017)Kathryn Foucar · University of New Mexico3 papers (2014–2017)Tracy I. George · University of Utah3 papers (2016–2021)Olga K. Weinberg · Boston Children's Hospital3 papers (2018–2019)Sanjay S. Patel · Royal Marsden NHS Foundation Trust3 papers (2018–2023)Leonardo Boiocchi · Memorial Sloan Kettering Cancer Center2 papers (2012–2014)Chi Young Ok · The University of Texas MD Anderson Cancer Center2 papers (2018–2019)Rashmi Kanagal‐Shamanna · The University of Texas MD Anderson Cancer Center2 papers (2014–2021)Paola Dal Cin · Harvard University2 papers (2016–2021)Jacqueline S. Garcia · Boston University2 papers (2018–2019)Keyur P. Patel · Mayo Clinic2 papers (2014–2021)